Figure 1 | Scientific Reports

Figure 1

From: Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy

Figure 1

Concentration of soluble programmed death ligand 1 (sPD-L1) in non-small cell lung cancer patients. (a) Concentration of sPD-L1 at the four sampling time points. Medians and interquartile ranges are illustrated. (b) Patients were divided in tertiles based on the sPD-L1 baseline level (red = high (n = 27), blue = medium (n = 27), green = low (n = 26)). Graphs illustrate the baseline level and dynamics of sPD-L1 in the subsequent samples in the three groups. (c) Dynamics of sPD-L1 in the two patients receiving atezolizumab measured using assays from two individual manufacturers. Open circles represent values above detection limit of the assay.

Back to article page